Goldman Sachs Group Inc. Grows Position in Meridian Bioscience Inc. (VIVO)
Goldman Sachs Group Inc. boosted its holdings in Meridian Bioscience Inc. (NASDAQ:VIVO) by 2.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,686 shares of the company’s stock after purchasing an additional 3,915 shares during the quarter. Goldman Sachs Group Inc. owned about 0.32% of Meridian Bioscience worth $2,153,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Meridian Bioscience by 9.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock valued at $63,299,000 after purchasing an additional 334,480 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Meridian Bioscience by 16.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,667,971 shares of the company’s stock valued at $26,271,000 after purchasing an additional 240,143 shares during the last quarter. State Street Corp raised its position in Meridian Bioscience by 15.2% in the 1st quarter. State Street Corp now owns 1,243,847 shares of the company’s stock valued at $17,164,000 after purchasing an additional 163,770 shares during the last quarter. Bank of New York Mellon Corp raised its position in Meridian Bioscience by 1.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 863,183 shares of the company’s stock valued at $13,595,000 after purchasing an additional 9,713 shares during the last quarter. Finally, Northern Trust Corp raised its position in Meridian Bioscience by 1.6% in the 2nd quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock valued at $8,780,000 after purchasing an additional 8,886 shares during the last quarter. Hedge funds and other institutional investors own 87.24% of the company’s stock.
In other Meridian Bioscience news, Chairman John A. Kraeutler acquired 7,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was purchased at an average price of $13.67 per share, with a total value of $95,690.00. Following the completion of the acquisition, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.30% of the company’s stock.
WARNING: “Goldman Sachs Group Inc. Grows Position in Meridian Bioscience Inc. (VIVO)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/10/31/goldman-sachs-group-inc-grows-position-in-meridian-bioscience-inc-vivo.html.
VIVO has been the subject of several research reports. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $14.00 price target on shares of Meridian Bioscience in a research report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. Meridian Bioscience presently has a consensus rating of “Hold” and an average target price of $14.00.
Shares of Meridian Bioscience Inc. (NASDAQ VIVO) opened at 14.70 on Tuesday. The company has a 50-day moving average of $14.56 and a 200 day moving average of $14.48. Meridian Bioscience Inc. has a 52-week low of $10.75 and a 52-week high of $18.58. The stock has a market cap of $620.38 million, a P/E ratio of 29.40 and a beta of 0.84.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.